Cardiovascular disease is the leading cause of death world-wide, affecting both men and women. Myocardial infarction and ischemic stroke are two severe consequences of cardiovascular disease caused by formation of an occlusive thr...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
LIPINTOECTION
Lipoproteins and angiogenesis A new look at an old problem
1M€
Cerrado
ANTCARD
Analogues Of Thromboxane For The Treatment Of Cardiovascular...
222K€
Cerrado
PID2019-108568RB-I00
MODULACION DE LAS CELULAS MUSCULARES LISAS EN LA PROGRESION...
230K€
Cerrado
PDC2022-133743-I00
ANTIAGREGANTES PLAQUETARIOS INHIBIDORES DEL RECEPTOR DE COLA...
132K€
Cerrado
SAF2013-42962-R
NUEVAS DIANAS DE INHIBICION DE LA TRANSFORMACION DE ATEROSCL...
460K€
Cerrado
COMPLEMENT AND LDL
COMPLEMENT AND ATHEROSCLEROSIS MOLECULAR MECHANISM OF C1 AC...
172K€
Cerrado
Información proyecto PAELLA
Duración del proyecto: 30 meses
Fecha Inicio: 2020-03-28
Fecha Fin: 2022-09-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Cardiovascular disease is the leading cause of death world-wide, affecting both men and women. Myocardial infarction and ischemic stroke are two severe consequences of cardiovascular disease caused by formation of an occlusive thrombus. Blood coagulation and thrombus formation is a complex interplay between clotting factors, platelets and endothelial cells lining the blood vessels that often involve interactions with leukocytes and other inflammatory cells. I propose to study a novel receptor on platelets, PEAR1, and its role in haemostasis, inflammation and thrombosis. I will use unique, synthetic poly-sulfated sugars that I have characterised as novel agents to activate PEAR1 and take advantage of the 30 years of experience of my host, Professor Watson, in studying platelet activation, and the recent identification (unpublished) of the natural ligand in the body which activates PEAR1. I will use state-of-the-art methodology available in Birmingham including flow chamber studies, CRISPR-CAS knock-down, phosphoproteomics, super-resolution and light sheet microscopy, intravital microscopy and a PEAR1 deficient mouse model to test my hypotheses that PEAR1 plays a critical role in thrombus stabilisation at sites of injury and drives thrombo-inflammatory disease in the vasculature. Uncovering the role of the novel receptor PEAR1 may lead to new treatment strategies to combat thrombosis.